Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) -- Preliminary Blinded Analysis of the European Sintra-REV Trial

Conclusions: In this preliminary and blinded analysis we confirm a high rate of erythroid and cytogenetic responses early (w12) after study treatment with an adequate safety profile. Unblinded data will be presented at the meeting.DisclosuresPlatzbecker: Celgene: Research Funding. Götze: JAZZ Pharmaceuticals: Honoraria; Takeda: Honoraria, Other: Travel aid ASH 2017; Novartis: Honoraria; Celgene: Honoraria, Research Funding. Díez-Campelo: Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Lopez Cadenas, F., Lumbreras, E., Xicoy, B., Sanchez-Garcia, J., Fenaux, P., Coll, R., Slama, B., Hernandez-Rivas, J. A., Thepot, S., Bernal, T., Arrizabalaga, B., Guerci, A., Sanz, G., Bargay, J., Amigo, M. L., de Paz, R., Giagounidis, A., Platzbecker, U Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Novel Therapeutics II Source Type: research